← Home / ARS Pharmaceuticals, Inc. (SPRY)
Stock Analysis
ARS Pharmaceuticals, Inc. (SPRY)
SPRY
SPRY · Market data
9.73 -1.77%
52W Range Position
26%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-06-18 18:29 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 9.78. Holding above 9.38 keeps the current thesis intact.
⚖️
Fundamentals
Strong / Negative
Price Structure
Constructive
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
Hold Above
Structure remains valid above support.
9.38
Break Above
Confirmation improves above resistance.
9.78
🎯
Next Objective
Pattern-derived target if setup continues.
12.11
×
Thesis Break
Scenario weakens below invalidation.
Below 9.38
What's Driving SPRY?
📈 Technical recovery is improving
Momentum is Neutral. Watch 9.78 for confirmation and 9.38 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 8.84 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
No confirmed breakout yet. Watch the next level and momentum behavior.
Pattern
Triangle Compression / SYM / UP
State
Forming
Breakout Watch
Downtrend line not broken yet · score 0
Compression
74%
RSI(14)
59.5
How to read this setup
The next meaningful technical decision is likely to occur between support at 8.84 and resistance at 9.79. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup. Pattern-based invalidation is near 6.82; losing that area would weaken the active formation considerably.
Price Chart
SPRY · WOI overlay chart
Open Full Workspace
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
Revenue Growth
Strong
Profitability
Negative
Cash Flow
Mixed
Balance Sheet
Stretched
💵 Revenue
22.68M
↗ Strong
📈 Net Income
-60.62M
↘ Negative
🧮 EPS (Basic)
-0.61
↘ Negative
ARS Pharmaceuticals, Inc.
Note: This is an algorithmic technical snapshot, not financial advice.